Trial Profile

A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Viagenpumatucel-L (Primary) ; Carboplatin
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms DURGA
Sponsors NightHawk Biosciences; Scorpius Holdings

Most Recent Events

06 Feb 2024 According to a NightHawk Biosciences media release, the NightHawk Biosciences has changed its name to Scorpius Holdings.
11 Nov 2022 Status changed from active, no longer recruiting to completed.
04 Oct 2022 Planned End Date changed from 1 Aug 2022 to 30 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com